FATE - Fate Therapeutics GAAP EPS of -$0.79 beats by $0.04 revenue of $18.55M beats by $5.99M
- Fate Therapeutics press release ( NASDAQ: FATE ): Q2 GAAP EPS of -$0.79 beats by $0.04 .
- Collaboration Revenue of $18.55M (+38.3% Y/Y) beats by $5.99M .
- Cash, cash equivalents and investments as of June 30, 2022 were $580.8 million.
For further details see:
Fate Therapeutics GAAP EPS of -$0.79 beats by $0.04, revenue of $18.55M beats by $5.99M